Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Core Viewpoint - Sichuan Shuangma announced that its subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has received the approval notice for the listing application of Acetyl-L-carnitine from the National Medical Products Administration [1] Group 1 - The approval is significant for the company as it expands its product offerings in the pharmaceutical sector [1] - The approval indicates a positive regulatory environment for the company's operations and potential growth in the biopharmaceutical market [1]

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Company Summary - Hubei Jianxiang Biopharmaceutical Co., Ltd. is now authorized to market Acetate Leuprolide, a GnRH agonist, which effectively suppresses the secretion of gonadotropins when administered continuously at therapeutic doses [1] - The approved indications for Acetate Leuprolide in China include treatment for endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

Core Viewpoint - Sichuan Shuangma (000935) announced that its subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Group 1: Company Developments - The approval pertains to Acetate Leuprolide, a Gonadotropin-Releasing Hormone (GnRH) agonist, which effectively suppresses the secretion of gonadotropins when administered at therapeutic doses [1] - The drug is currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

格隆汇10月16日丨四川双马(000935.SZ)公布，控股子公司湖北健翔生物制药有限公司（简称"湖北健 翔"）于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。醋酸 亮丙瑞林是一种促性腺激素释放激素（GnRH）激动剂，治疗剂量下持续给药可有效抑制促性腺激素的 分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经前乳腺癌、中 枢性性早熟的治疗。 ...

四川双马(000935.SZ)公告称，公司控股子公司湖北健翔生物制药有限公司近日获得国家药品监督管理 局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。该原料药已符合国家相关原料药审评技术 要求，可在国内市场进行生产销售，进一步丰富了公司产品线，强化了公司在国内原料药细分领域的竞 争优势。但需注意医药产业特点及市场环境等因素影响，存在不确定性。 ...

四川双马（000935）(000935.SZ)公告，公司控股子公司湖北健翔生物制药有限公司(简称"湖北健翔")于 近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。 公告显示，醋酸亮丙瑞林是一种促性腺激素释放激素(GnRH)激动剂，治疗剂量下持续给药可有效抑制 促性腺激素的分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经 前乳腺癌、中枢性性早熟的治疗。 ...

智通财经APP讯，四川双马(000935.SZ)公告，公司控股子公司湖北健翔生物制药有限公司(简称"湖北健 翔")于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。 公告显示，醋酸亮丙瑞林是一种促性腺激素释放激素(GnRH)激动剂，治疗剂量下持续给药可有效抑制 促性腺激素的分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经 前乳腺癌、中枢性性早熟的治疗。 ...